Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections

Fineline Cube Feb 17, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...

Company Drug

Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment

Fineline Cube Feb 17, 2025

The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...

Company Deals

Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study

Fineline Cube Feb 17, 2025

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...

Company Drug

GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25

Fineline Cube Feb 17, 2025

UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...

Company Deals

3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China

Fineline Cube Feb 17, 2025

China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...

Company Drug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

Fineline Cube Feb 17, 2025

Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...

Company Drug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Fineline Cube Feb 17, 2025

China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...

Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

Fineline Cube Feb 15, 2025

Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...

Company Digital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

Fineline Cube Feb 15, 2025

On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...

Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

Fineline Cube Feb 14, 2025

Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...

Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Company Drug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Fineline Cube Feb 14, 2025

US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...

Company Drug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

Fineline Cube Feb 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...

Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials

Fineline Cube Feb 14, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...

Company Drug

Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib

Fineline Cube Feb 14, 2025

Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...

Posts pagination

1 … 244 245 246 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.